---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043932"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:36:02.014935+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients

## Summary
- 16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.
- Statistically significant increases in IFNγ (P=0.03) and IL-17 (P=0.0001) over baseline.
- Dose Level 1 determined as immunologic and maximum tolerated dose; no serious adverse events besides injection site irritation.
- Plans to evaluate vaccine with Keytruda in residual disease cohort and in BRCA/PALB2 mutation carriers.
- CEO says data exceeded expectations; Phase 2/3 planning underway.

## SEC filing metadata
- accession: 0001493152-23-043932
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315223043932/0001493152-23-043932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315223043932/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043932
- JSON: https://secwatch.observer/filing/0001493152-23-043932.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.